ZIM Laboratories Gets Indian Regulator's Nod for Naproxen + Esomeprazole Capsules

MT Newswires Live12-03 17:23

ZIM Laboratories (NSE:ZIMLAB, BOM:541400) has received approval from India's Central Drugs Standard Control Organisation to manufacture and market fixed dose combination (FDC) of Naproxen Delayed Release and Esomeprazole capsule (375mg/500mg + 20mg/ 20mg), according to a Wednesday filing to the Indian stock exchanges.

The combination drug is used to treat osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, and to reduce the risk of nonsteroidal anti-inflammatory drug (NSAID)-associated gastric and duodenal ulcers.

ZIM has already signed a commercial supply agreement with an Indian pharmaceutical company for the product and is targeting a commercial launch in India in the financial year 2026-27.

The company's shares were down nearly 1% in recent trade.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2588014391?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-03 17:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2588014391","market":"fut","top_or_hot":-1,"title":"ZIM Laboratories Gets Indian Regulator's Nod for Naproxen + Esomeprazole Capsules","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/ZIM\">ZIM</a> Laboratories (NSE:ZIMLAB, BOM:541400) has received approval from India's Central Drugs Standard Control Organisation to manufacture and market fixed dose combination (FDC) of Naproxen Delayed Release and Esomeprazole capsule (375mg/500mg + 20mg/ 20mg), according to a Wednesday filing to the Indian stock exchanges.</p><p>The combination drug is used to treat osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, and to reduce the risk of nonsteroidal anti-inflammatory drug (NSAID)-associated gastric and duodenal ulcers.</p><p>ZIM has already signed a commercial supply agreement with an Indian pharmaceutical company for the product and is targeting a commercial launch in India in the financial year 2026-27.</p><p>The company's shares were down nearly 1% in recent trade.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ZIM Laboratories Gets Indian Regulator's Nod for Naproxen + Esomeprazole Capsules</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nZIM Laboratories Gets Indian Regulator's Nod for Naproxen + Esomeprazole Capsules\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-12-03 17:23</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/ZIM\">ZIM</a> Laboratories (NSE:ZIMLAB, BOM:541400) has received approval from India's Central Drugs Standard Control Organisation to manufacture and market fixed dose combination (FDC) of Naproxen Delayed Release and Esomeprazole capsule (375mg/500mg + 20mg/ 20mg), according to a Wednesday filing to the Indian stock exchanges.</p><p>The combination drug is used to treat osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, and to reduce the risk of nonsteroidal anti-inflammatory drug (NSAID)-associated gastric and duodenal ulcers.</p><p>ZIM has already signed a commercial supply agreement with an Indian pharmaceutical company for the product and is targeting a commercial launch in India in the financial year 2026-27.</p><p>The company's shares were down nearly 1% in recent trade.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2588014391","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2588014391","pubTimestamp":1764753835,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"ZIM Laboratories  has received approval from India's Central Drugs Standard Control Organisation to manufacture and market fixed dose combination  of Naproxen Delayed Release and Esomeprazole capsule , according to a Wednesday filing to the Indian stock exchanges.The combination drug is used to treat osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, and to reduce the risk of nonsteroidal anti-inflammatory drug -associated gastric and duodenal ulcers.ZIM has already signed a commercial supply agreement with an Indian pharmaceutical company for the product and is targeting a commercial launch in India in the financial year 2026-27.The company's shares were down nearly 1% in recent trade.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","ZIM":"以星航运","BK4021":"海运","BK4588":"碎股"},"translate_title":"以星实验室萘普生+埃索美拉唑胶囊获得印度监管机构批准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ZIM":1.5},"content_text":"ZIM Laboratories (NSE:ZIMLAB, BOM:541400) has received approval from India's Central Drugs Standard Control Organisation to manufacture and market fixed dose combination (FDC) of Naproxen Delayed Release and Esomeprazole capsule (375mg/500mg + 20mg/ 20mg), according to a Wednesday filing to the Indian stock exchanges.The combination drug is used to treat osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, and to reduce the risk of nonsteroidal anti-inflammatory drug (NSAID)-associated gastric and duodenal ulcers.ZIM has already signed a commercial supply agreement with an Indian pharmaceutical company for the product and is targeting a commercial launch in India in the financial year 2026-27.The company's shares were down nearly 1% in recent trade.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2588014391","isCrawlerRequest":true}